BETA - What is the future of acute myeloid leukemia treatment?

What is the future of AML treatment? Targeted agents in acute myeloid leukemia has revolutionized the care. So if we talk about our foot three mutated patients, those are patients who not that We would classify them as relatively poor risk without an agent to keep their leukemia away. So sometimes it wasn't too difficult to get it to go away, but it would keep coming back time and time again. And then along came these foot three inhibitors that knocked down the thing that's telling this AML to go. Right. So those have absolutely changed the survival for patients with the foot three mutated AML. It used to be very low and now over 80 percent of patients can be cured of this leukemia. So we now have other levels of targeted agents. So we have our IDH inhibitors for patients who have IDH mutations. We have Venetoclax, which is a more global mechanism of action. It's not specifically targeted at any one thing, but it has a lot of activity against a lot of different subtypes of AML. So Venetoclax was the next huge win for us. And the space that we're in right now is really optimizing a lot of these different agents. How do we combine them together to move patients forward in terms of the novel treatments that are coming along? The next big class of targeted agents that will be set for approval are the men and inhibitors. So there is a very adverse risk type of acute myeloid leukemia that's got this KMT to a rearrangement. This can sometimes be seen in therapy related leukemias, and sometimes it can just pop out of nowhere. These patients we know have a really tough time keeping their leukemia away. And men and inhibitors work in this pathway to help extend the survival for these patients. So there is a whole lot of activity in the men and inhibition space. So that's the next big round of progress that's coming. We're also seeing targeted antibodies. We're seeing antibody drug conjugates, which are bringing toxins or radiation directly to leukemia cells. And we're seeing a number of novel immunotherapies. I think immunotherapy finally is starting to make a difference in AML, but not once targeting T cells necessarily, but other mechanisms, macrophages, the bone marrow microenvironment. So CD47 and TEM3A are some novel immunotherapeutic targets that we're looking at with antibodies. Very, very excited. All of these are non cytotoxic drugs, not conventional chemo, and kind of, I think, represent where we're going.